Genmab.
Danish healthcare company
- Reports this week
- 3
- Active events
- 3
- Connections
- 57
What's happening
Active this week
-
Genmab, a Danish biotechnology company, granted stock units and warrants via its Board of Directors on September 1, 2026.Some support2 reports
-
Regeneron, Halozyme, and Genmab are noted as holdings in specific healthcare sector ETFs, SPDR and FBT.Some support1 report
-
Corbus Pharmaceuticals discussed Genmab's results concerning head and neck cancer.Some support1 report
Earlier this month
-
Genmab and Incyte have entered into a collaboration to evaluate new cancer treatments.Some support5 reports
-
Genmab's results are advancing its ambition to lead in the field of gynecologic oncology.Some support1 report
-
Truist Financial started coverage on Genmab shares, and TD Cowen raised rating and price target for the company, which trades on Nasdaq.Well supported4 reports
-
BioNTech announced new partnerships with Genmab, Pfizer, Bristol-Myers Squibb, and Genentech.Some support1 report
One to three months ago
Gone quiet
No new reports in 90+ days-
CSG, Novo Nordisk, and Genmab were confirmed as constituents of the STOXX 600 index.Some support3 reports
-
Genmab listed its shares on the stock exchange on August 6, 2026.Some support1 report
-
Genmab, headquartered in Denmark, is issuing interim financial reports and monitoring the Japanese market.Some support1 report
-
AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.Well supported8 reports1 development inside
-
A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.Some support1 report
-
A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.Some support6 reports1 development inside
-
Genmab is headquartered in Copenhagen.Well supported9 reports
-
Genmab A/S ADR is now listed on the NASDAQ stock exchange.Some support8 reports
-
Genmab, a Denmark-based biotechnology company headquartered in Copenhagen, partnered with Janssen for commercialization.Some support1 report
-
Genmab's Board of Directors granted stock units and warrants on June 1, 2026.Some support2 reports
-
FDA granted Breakthrough Therapy Designation for Genmab's Rina-S, while the company also faces potential challenges from Trump's tariffs.Well supported4 reports
-
Greg Mueller joined Genmab as Executive Vice President, moving from AstraZeneca.Speculative1 report
-
Morgan Stanley assigned an Equal-Weight rating to Genmab on July 3, 2025.Speculative1 report
-
Genmab reported increased royalties from its DARZALEX collaboration with Johnson & Johnson, while UBS maintained a Buy rating on the company.Well supported5 reports
-
Steve Cohen recommended Genmab as a buy, and Truist Securities raised its price target for the company.Some support1 report
-
Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.Some support2 reports
-
Scott Cenci previously worked at Genmab, Biogen, Zoetis, and Pfizer.Some support1 report
-
Genmab faces uncertainty regarding regulatory approvals from the FDA.Some support3 reports
-
Genmab, Bolt Biotherapeutics, and Toray are advancing multiple development candidates, with collaborations with Toray progressing and a Phase 1 study underway in Australia.Some support1 report
-
Pfizer and Genmab are collaborating on TIVDAK, which combines Genmab's antibody with Pfizer's ADC technology.Some support3 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Genmab
Events traced to Genmab, step by step, newest first- AbbVie's pipeline growth could strengthen partnership with GenmabAbbVie's pipeline boost may increase the strategic value of its partnership with GenmabPossible
- JNJ's strong financials may boost Genmab's royalty revenueJNJ's strong financials may boost Genmab's royalty revenuePossible
- AbbVie's new therapy approvals strengthen Genmab partnershipAbbVie's new therapy approvals strengthen joint development partnership with GenmabLikely
- Genmab may gain from strong Darzalex sales at Johnson & JohnsonGenmab may benefit from strong sales of Johnson & Johnson's DarzalexLikely
Around Genmab this week
News at the entities that move Genmab most-
Johnson & Johnson StructuralDuke Energy, Johnson & Johnson, Microsoft, and Welltower are large positions in the iShares MSCI USA Min Vol Factor ETF amid investor angst.Moves Genmab
-
AbbVie OperationalDHS leans on AbbVie, Altria, and Merck for stock weighting, while the SEC legally requires fiduciaries to prioritize client interests.Moves Genmab
-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Genmab
-
board of directors StructuralAlbert is appointed CEO and reports to the board of directors.Moves Genmab
-
Copenhagen Shared contextThe University of Copenhagen conducted a study on climate adaptation within the city.Moves Genmab
-
Novartis TransactionalBristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.Moves Genmab
Connections
The 30 strongest of 57, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AbbVie Operational
AbbVie and Genmab maintain a formal partnership for joint drug development, clinical trials, and commercialization, including profit-sharing.
-
Johnson & Johnson Structural
Genmab receives royalty revenue from Johnson & Johnson's commercialization of daratumumab under an exclusive license agreement.
-
FDA Structural
The FDA structurally regulates Genmab's drug development, reviewing submissions and granting designations.
-
Nasdaq Structural
Genmab is a publicly traded company whose shares are listed and traded on the Nasdaq exchange.
-
Jan Van de Winkel Structural
Jan Van de Winkel serves as the CEO and President of Genmab.
-
board of directors Structural
The Board of Directors formally grants stock units and warrants to Genmab as part of its corporate governance.
-
Janssen Transactional
Genmab and Janssen have entered into a partnership regarding the commercialization of the product daratumumab.
-
Novartis Transactional
Genmab receives royalty revenue from Novartis stemming from their collaboration on Kesimpta.
Show all 30 connections
-
TD Cowen Transactional
TD Cowen issued rating upgrades and target price increases for Genmab.
-
Danish Business Authority Structural
Genmab's operation requires formal registration and compliance with the standards set by the Danish Business Authority.
-
Renaissance Technologies Transactional
Renaissance Technologies has made a current investment in Genmab stock.
-
Copenhagen Shared context
Genmab is headquartered and operates from Copenhagen.
-
Securities and Exchange Commission Structural
Genmab operates under the formal regulatory oversight and filing requirements of the Securities and Exchange Commission.
-
FBT Structural
FBT holds Genmab in its investment portfolio.
-
Incyte Operational
Genmab and Incyte are collaborating on the evaluation and assessment of novel cancer treatments.
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial ratings and price targets for Genmab.
-
FED Operational
Genmab's strong financial results influence market sentiment regarding the Federal Reserve's rate hike expectations.
-
Truist Financial Mentioned together
Truist Financial provides investment coverage and ratings on Genmab shares.
-
LinkedIn Mentioned together
Genmab utilizes LinkedIn as a platform for corporate presence and communication.
-
Denmark Shared context
Genmab is consistently described as being headquartered or operating from Denmark.
-
Europe Structural
Genmab is included in the STOXX 600 index, which represents the market structure of Europe.
-
European Society for Medical Oncology Operational
Genmab presented its clinical findings at the European Society for Medical Oncology Congress.
-
Reuters Mentioned together
Reuters, a major global news agency, reports on the stock performance of the biotech company Genmab.
-
Utrecht Shared context
Genmab maintains R&D facilities located within the city of Utrecht.
-
MarketBeat Mentioned together
MarketBeat provides consensus rating data regarding Genmab.
-
Goldman Sachs Mentioned together
No direct coupling between Goldman Sachs and Genmab was observed in the provided evidence.
-
Corbus Pharmaceuticals Operational
Corbus Pharmaceuticals discusses Genmab's results in the head and neck cancer therapeutic area.
-
Gynecologic Oncology Group Shared context
Genmab operates within the field of gynecologic oncology, advancing ambition to lead in the sector.
-
Michael Schmidt Mentioned together
No evidence links Michael Schmidt to Genmab in the provided timeline.
-
Asia Shared context
Genmab is mentioned in the context of corporate earnings reports related to market sentiment in Asia.
History
Events by the month they beganNovember 2026
2 eventsOctober 2026
3 eventsSeptember 2026
2 eventsShow 2 earlier months
August 2026
3 eventsJune 2026
18 events- AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.
- AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.
- A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.
- A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.
- Genmab is headquartered in Copenhagen.
- Genmab A/S ADR is now listed on the NASDAQ stock exchange.
- Genmab, a Denmark-based biotechnology company headquartered in Copenhagen, partnered with Janssen for commercialization.
- Genmab's Board of Directors granted stock units and warrants on June 1, 2026.
- FDA granted Breakthrough Therapy Designation for Genmab's Rina-S, while the company also faces potential challenges from Trump's tariffs.
- Greg Mueller joined Genmab as Executive Vice President, moving from AstraZeneca.
- Morgan Stanley assigned an Equal-Weight rating to Genmab on July 3, 2025.
- Genmab reported increased royalties from its DARZALEX collaboration with Johnson & Johnson, while UBS maintained a Buy rating on the company.
- Steve Cohen recommended Genmab as a buy, and Truist Securities raised its price target for the company.
- Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.
- Scott Cenci previously worked at Genmab, Biogen, Zoetis, and Pfizer.
- Genmab faces uncertainty regarding regulatory approvals from the FDA.
- Genmab, Bolt Biotherapeutics, and Toray are advancing multiple development candidates, with collaborations with Toray progressing and a Phase 1 study underway in Australia.
- Pfizer and Genmab are collaborating on TIVDAK, which combines Genmab's antibody with Pfizer's ADC technology.